Read all of this leaflet carefully before you start taking this medicine. If you have further questions, please ask your doctor or pharmacist.

Size: px
Start display at page:

Download "Read all of this leaflet carefully before you start taking this medicine. If you have further questions, please ask your doctor or pharmacist."

Transcription

1 INFORMATION FOR THE PATIENT ABOUT OxyContin Prolonged Release Tablets Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you personally. Do not share your medicine with other people. It may harm them, even if their symptoms are the same as yours. SCHEDULING STATUS: S6 PROPRIETARY NAME (and Dosage Form): OxyContin 5 mg Prolonged Release Tablets (Tablets) OxyContin 10 mg Prolonged Release Tablets (Tablets) OxyContin 20 mg Prolonged Release Tablets (Tablets) OxyContin 40 mg Prolonged Release Tablets (Tablets) OxyContin 80 mg Prolonged Release Tablets (Tablets) 1. WHAT OxyContin Prolonged Release Tablets CONTAINS: Each OxyContin 5 mg Prolonged Release Tablet contains 5 mg of oxycodone hydrochloride. Each OxyContin 10 mg Prolonged Release Tablet contains 10 mg of oxycodone hydrochloride. 1

2 Each OxyContin 20 mg Prolonged Release Tablet contains 20 mg of oxycodone hydrochloride. Each OxyContin 40 mg Prolonged Release Tablet contains 40 mg of oxycodone hydrochloride. Each OxyContin 80 mg Prolonged Release Tablet contains 80 mg of oxycodone hydrochloride. In addition OxyContin Prolonged Release Tablets contain the following inactive ingredients in the tablet core: Lactose monohydrate, Povidone K30, Ammonio methacrylate co-polymer, Sorbic acid, Triacetin, Stearyl alcohol, Talc and Magnesium stearate. The tablet coating contains the following ingredients: OxyContin 5 mg Prolonged Release Tablet: Hypromellose (E464), Macrogol 400, Titanium Dioxide (E171), Brilliant Blue (E133). OxyContin 10 mg Prolonged Release Tablet: Hypromellose (E464), Hyprolose, Macrogol 400, Titanium Dioxide (E171). OxyContin 20 mg Prolonged Release Tablet: Hypromellose (E464), Macrogol 400, Polysorbate 80, Titanium Dioxide (E171), Iron Oxide (E172). OxyContin 40 mg Prolonged Release Tablet: Hypromellose (E464), Macrogol 400, Polysorbate 80, Titanium Dioxide (E171), Iron Oxide (E172). OxyContin 80 mg Prolonged Release Tablet: Hypromellose (E464), Hyprolose, Macrogol 400, Titanium Dioxide (E171), Iron Oxide (E172), Indigo carmine (E132). 2. WHAT OxyContin Prolonged Release Tablets ARE USED FOR: OxyContin Prolonged Release Tablet is a strong analgesic or painkiller and belongs to the group opioids. OxyContin Prolonged Release Tablet is used for the relief of moderate to severe pain in patients with cancer and post-operative pain, after gastrointestinal function has returned. 2

3 OxyContin Prolonged Release Tablet is used for the relief of severe pain requiring the use of a strong opioid analgesic. 3. BEFORE TAKING OxyContin Prolonged Release Tablets: Do not take OxyContin Prolonged Release Tablets if you are allergic (hypersensitive) to the active ingredient oxycodone hydrochloride or any of the other ingredients; if you suffer from severe breathing problems with a lowered supply of oxygen to the blood (hypoxia) and/or increased carbon dioxide saturation of the blood (hypercapnia); if you suffer from a long-term (chronic) obstructive lung disease; if you have a heart problem after long-term lung disease (cor pulmonale); if you suffer from long-term (chronic) bronchial asthma; where the small bowel does not work properly (paralytic ileum); during pregnancy and breast-feeding; in the presence of severe lung-, liver- or kidney diseases; if you are taking a type of medicine known as a monoamine oxidase inhibitor or if you have taken this type of medicine in the last two weeks; in any situation where opioids are contra-indicated; if you suffer from a head injury that causes a severe headache or makes you feel sick; if you suffer from severe pain in your abdomen; if your stomach empties more slowly than it should (delayed gastric emptying); if you suffer from on-going constipation (hard, infrequent stools); for 6 hours before an operation or for the first 24 hours after an operation; if you suffer from rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. 3

4 Take special care with OxyContin Prolonged Release Tablets with elderly or weakened patients; if you have an under-active thyroid (hypothyroidism), as you may need a lower dose of OxyContin Prolonged Release Tablets; if you have poor adrenal gland function (Addison s disease); if you have prostate problems; if you have a mental disorder as a result of an infection (toxic psychosis); if you are or ever have been addicted to alcohol or drugs; if you have previously suffered from withdrawal symptoms such as agitation, anxiety; shaking or sweating, upon stopping taking alcohol or drugs; if you have inflammation of the pancreas (pancreatitis) or problems with your gall bladder; if you have a severe headache or feel sick as this may indicate that the pressure in your skull is increased; if you have low blood pressure (hypotension) or low blood volume (hypovolemia), if you have inflammatory bowel disease. If this information applies to you or formerly applied to you, please speak to your doctor. Use OxyContin Prolonged Release Tablets with special caution in cases if you are or ever have been addicted to alcohol or drugs. OxyContin 80 mg Prolonged Release Tablets OxyContin 80 mg Prolonged Release Tablets should not be taken by patients, who have not taken opioids before, as their potency may lead to a life-threatening respiratory depression in this group of patients. 4

5 Children and Adolescents under 18 years of age OxyContin Prolonged Release Tablets OxyContin Prolonged Release Tablets has not been tested in children and adolescents under 18 years of age. Therefore safety and efficacy are not established and OxyContin Prolonged Release Tablets is not recommended in children and adolescents under 18 years of age. Elderly persons In elderly patients without liver and/or kidney disease, a dose adjustment is usually unnecessary. Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. If you take OxyContin Prolonged Release Tablets with some other medicines, the effect of OxyContin Prolonged Release Tablets or the other medicine may be changed. OxyContin Prolonged Release Tablets must not be used together with a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or if you have taken this type of medicine in the last two weeks. Tell your doctor or pharmacist: if you are taking medicines to help you sleep (for example tranquillisers, hypnotics or sedatives); if you have recently been given an anaesthetic; if you are taking medicines to treat depression; if you are taking medicines to treat psychiatric or mental disorders; 5

6 if you are taking other strong analgesics or painkillers ; if you are taking muscle relaxants; if you are taking medicines to treat high blood pressure; if you are taking quinidine (a medicine to treat a fast heart beat); if you are taking cimetidine (a medicine for stomach ulcers, indigestion or heartburn); if you are taking antifungal medicines (such as ketoconazole); if you are taking antibiotics (such as erythromycin). Taking OxyContin Prolonged Release Tablets with food and drink You can take OxyContin Prolonged Release Tablets with or without food. Drinking alcohol during your treatment with OxyContin Prolonged Release Tablets may make you sleepy. If you are affected you should avoid drinking alcohol. Pregnancy and breast-feeding Do not take OxyContin Prolonged Release Tablets during pregnancy. The active ingredient oxycodone is transported through the placenta to the organism of the child. The long-term use of OxyContin Prolonged Release Tablets during pregnancy may lead to withdrawal symptoms in newborn infants. If taken during birth, breathing problems may occur in the child. Do not take OxyContin Prolonged Release Tablets during periods of breast-feeding, since the active substance oxycodone may pass into the breastmilk. Ask your doctor or pharmacist for advice before taking/using any medicine. Driving and using machines You may feel sleepy when you first start taking OxyContin Prolonged Release Tablets, or when changing to a higher dose. If you are affected you should not drive or use machinery. 6

7 Important information about some of the ingredients of OxyContin Prolonged Release Tablets OxyContin Prolonged Release Tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking OxyContin Prolonged Release Tablets. 4. HOW TO TAKE OxyContin Prolonged Release Tablets Always take OxyContin Prolonged Release Tablets exactly as your doctor has told you. Do not exceed the dose recommended by your doctor. You should check with your doctor or pharmacist if you are not sure. Unless otherwise prescribed by your doctor, the usual dose for adults older than 18 years old is one prolonged release tablet of OxyContin 10 mg Prolonged Release Tablets (10 mg oxycodone hydrochloride) at 12 hour intervals. Some patients may benefit from a starting dose of 5 mg to minimise the side-effects. However, your doctor will prescribe the dose required to treat your pain. If you find that you are still in pain, or the effect too strong whilst taking OxyContin Prolonged Release Tablets, discuss this with your doctor. Swallow the prolonged-release tablets whole in order not to weaken the release of the active ingredient over an extended period of time (prolonged-release). Some patients receiving OxyContin Prolonged Release Tablets on a fixed time schedule require immediate-release painkillers for fast relief from breakthrough pain. OxyContin Prolonged Release Tablets are not intended for the treatment of breakthrough pain. 7

8 Elderly persons In elderly patients without kidney and/or liver disease, dosage adjustment is usually not necessary. High-risk patients Patients with kidney and/or liver disease who have not received opioids before should initially take half of the recommended adult dose. This also applies to patients with low body weight and patients who metabolise medications at slower rates. Method of administration and duration of use Swallow the prolonged-release tablets without chewing and with sufficient liquid (half a glass of water) in the morning and evening in accordance to a fixed time schedule (e.g. in the morning at 8 a.m., in the evening at 8 p.m.). You can take OxyContin Prolonged Release Tablets with or without food. In order to avoid weakening the prolonged release effect of the tablets, the prolonged release tablets must be swallowed whole and are not allowed to be broken, chewed or crushed. Taking broken, chewed or crushed tablets leads to speedier release of the active ingredient and to the absorption of a potentially fatal dose of the active ingredient oxycodone (see under If you take more OxyContin Prolonged Release Tablets than you should ). OxyContin Prolonged Release Tablets are for oral use only (swallowing of whole tablets). Improper injection (injection into a blood vessel) of the dissolved tablets must not be done, because this may lead to serious side-effects which may be fatal. 8

9 You may see residue of the tablet in your stool. Do not worry, as the active ingredient oxycodone has been released earlier while the tablet passed through the gastric system and have started to be effective in your body. If you take more OxyContin Prolonged Release Tablets than you should or if someone accidentally swallows your tablets Call your doctor or hospital straight away. People who have taken an overdose may feel very sleepy and sick. They may also have breathing difficulties leading to unconsciousness or even death and may need emergency treatment in hospital. When seeking medical attention make sure that you take this leaflet and any remaining tablets with you to show to the doctor. If you forget to take OxyContin Prolonged Release Tablets If you take a smaller dose of OxyContin Prolonged Release Tablets than prescribed, or if you have completely forgotten to take your dose, this will lead to unsatisfactory and/or insufficient pain relief. If you have forgotten to take your dose once, you may take it later only if the next regular dose was scheduled more than 8 hours later. You may then continue to follow your usual schedule. If the time to the next dose is shorter, take the prolonged-release tablets, but postpone the next dose by 8 hours. As a matter of principle, you should never take OxyContin Prolonged Release Tablets more frequently than at 8-hourly intervals. Never take a doubled amount of a single dose. 9

10 If you stop taking OxyContin Prolonged Release Tablets Do not stop taking OxyContin Prolonged Release Tablets without telling your doctor. If you want to stop taking your tablets, discuss this with your doctor first. They will tell you how to do this, usually by reducing the dose gradually so you do not experience unpleasant effects. If you have any further questions on the use of this product, ask your doctor or pharmacist. 5. POSSIBLE SIDE EFFECTS Like all medicines, OxyContin Prolonged Release Tablets can cause side effects, although not everybody gets them. All medicines can cause allergic reactions, although serious allergic reactions are rare. Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. The most serious side effect is a condition where you breathe more slowly or weakly than expected (respiratory depression). As with all strong painkillers, there is a risk that you may become addicted or reliant on OxyContin Prolonged Release Tablets. Common side effects (Probably affecting more than 1 in 100 people taking OxyContin Prolonged Release Tablets.) Most people will have constipation when they take OxyContin Prolonged Release Tablets. Your doctor can prescribe a laxative to overcome this problem. You may feel sick or vomit (be sick) when you take these prolonged release tablets, this should normally wear off after a few days however your doctor can prescribe an anti-vomiting medicine if it continues to be a problem. 10

11 You may find that you feel more sleepy than normal when you start taking your tablets or when your dose is increased. This should wear off after a few days. The following side effects have also been commonly reported in patients treated with OxyContin Prolonged Release Tablets: Dry mouth, loss of appetite, indigestion, abdominal pain or discomfort, diarrhoea; Headache, confusion, a feeling of unusual weakness, dizziness, anxiety, nervousness, twitching, difficulty in sleeping, abnormal thoughts or dreams; Difficulty in breathing or wheezing, shortness of breath, decreased cough reflex; Rash, itchy skin; Sweating, chills. Uncommon side effects (Probably affecting fewer than 1 in 100 people taking OxyContin Prolonged Release Tablets) Difficulty in swallowing, belching, hiccups, wind, gastrointestinal disorders (e.g. upset stomach), changes in taste; A feeling of dizziness or spinning, a feeling of faintness especially on standing up, hallucinations, mood changes, depression, a feeling of extreme happiness, restlessness, agitation, generally feeling unwell, loss of memory, shaking, difficulties with speech, reduced sensitivity to pain or touch, tingling or numbness, seizures, fits or convulsions, blurred vision; Difficulty in passing urine, impotence, decreased sexual drive, absence of menstrual periods; Fast heart beat, low blood pressure, flushing of the skin; Dehydration, thirst, swelling of the hands, ankles or feet; Dry skin, severe flaking or peeling of the skin; Redness of the face, reduction in size of the pupils in the eye, muscle spasm, high 11

12 temperature; A need to take increasingly higher doses of OxyContin Prolonged Release Tablets to gain the same level of pain relief (tolerance); Withdrawal symptoms such as agitation, anxiety, palpitations, shaking or sweating upon stopping taking OxyContin Prolonged Release Tablets. Uncommonly, OxyContin Prolonged Release Tablets may affect the results of blood tests to check that your liver is working properly. Not all side-effects reported for OxyContin Prolonged Release Tablets are included in this leaflet. Should any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please consult your doctor, pharmacist or other healthcare professional for advice. 6. HOW TO STORE OxyContin Prolonged Release Tablets Keep out of the reach and sight of children. Store below 25 ºC. Store in original package in the outer carton in order to protect from light. Do not use OxyContin Prolonged Release Tablets after the expiry date which is stated on the blister and carton after Expiry date. The expiry date refers to the last day of that month. 7. PRESENTATION OF OxyContin Prolonged Release Tablets OxyContin 5 mg Prolonged Release Tablets are supplied in clear PVC and aluminium foil blister packs of 28. OxyContin 10 mg Prolonged Release Tablets are supplied in clear PVC and aluminium foil blister packs of 28. OxyContin 20 mg Prolonged Release Tablets are supplied in clear PVC and aluminium foil blister packs of 28. OxyContin 40 mg Prolonged Release Tablets are supplied in clear PVC and aluminium foil blister packs of

13 OxyContin 80 mg Prolonged Release Tablets are supplied in clear PVC and aluminium foil blister packs of IDENTIFICATION OF OxyContin Prolonged Release Tablets OxyContin 5 mg Prolonged Release Tablets are pale blue, round, bi-convex, film coated tablets, imprinted with OC on one side and 5 on the other side. OxyContin 10 mg Prolonged Release Tablets are white, round, bi-convex, film coated tablets, imprinted with OC on one side and 10 on the other side. OxyContin 20 mg Prolonged Release Tablets are pink, round, bi-convex, film coated tablets, imprinted with OC on one side and 20 on the other side. OxyContin 40 mg Prolonged Release Tablets are yellow, round, bi-convex, film coated tablets, imprinted with OC on one side and 40 on the other side. OxyContin 80 mg Prolonged Release Tablets are green, round, bi-convex, film coated tablet, imprinted with OC on one side and 80 on the other side. 9. REGISTRATION NUMBERS OxyContin 5 mg Prolonged Release Tablets: 41/2.9/1098 OxyContin 10 mg Prolonged Release Tablets: 41/2.9/1099 OxyContin 20 mg Prolonged Release Tablets: 41/2.9/1100 OxyContin 40 mg Prolonged Release Tablets: 41/2.9/1101 OxyContin 80 mg Prolonged Release Tablets: 41/2.9/ NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION Mundipharma (Pty) Ltd P.O. Box Claremont 13

14 7735 South Africa 11. DATE OF PUBLICATION OF THIS PATIENT INFORMATION LEAFLET 9 October 2009 = OxyContin is a registered trademark 14

15 INLIGTING VIR DIE PASIËNT AANGAANDE OxyContin Prolonged Release Tablets Lees hierdie hele pamflet sorgvuldig deur voordat u hierdie medisyne begin gebruik. Bewaar hierdie pamflet. U mag dit nodig vind om dit weer te lees. Indien u verdere vrae het, vra asseblief u geneesheer of apteker. Hierdie medisyne is vir u persoonlik voorgeskryf. Moet nie u medisyne met ander mense deel nie. Dit kan hulle benadeel, al is hul simptome dieselfde as joune. SKEDULERINGSTATUS: S6 EIENDOMSNAAM (en Doseervorme): OxyContin 5 mg Prolonged Release Tablets (Tablette) OxyContin 10 mg Prolonged Release Tablets (Tablette) OxyContin 20 mg Prolonged Release Tablets (Tablette) OxyContin 40 mg Prolonged Release Tablets (Tablette) OxyContin 80 mg Prolonged Release Tablets (Tablette) 1. WAT BEVAT OxyContin Prolonged Release Tablets: Elke OxyContin 5 mg Prolonged Release Tablet bevat 5 mg oksikodoonhidrochloried. Elke OxyContin 10 mg Prolonged Release Tablet bevat 10 mg oksikodoonhidrochloried. Elke OxyContin 20 mg Prolonged Release Tablet bevat 20 mg oksikodoonhidrochloried. Elke OxyContin 40 mg Prolonged Release Tablet bevat 40 mg oksikodoonhidrochloried. Elke OxyContin 80 mg Prolonged Release Tablet bevat 80 mg oksikodoonhidrochloried. 15

16 Daarbenewens bevat OxyContin Prolonged Release Tablets die volgende onaktiewe bestanddele in die tabletkern: Laktosemonohidraat, Povidoon K30, Ammoniometakrilaat ko-polimeer, Sorbiensuur, Triasetien, Stearielalkohol, Talkum, Magnesiumstearaat. Die tabletbedekking bevat die volgende bestanddele: OxyContin 5 mg Prolonged Release Tablet: Hipromellose (E464), Makrogol 400, Titaniumdioksied (E171), Brilliant Blue (E133) kleurstof. OxyContin 10 mg Prolonged Release Tablet: Hipromellose (E464), Hiprolose, Makrogol 400, Titaniumdioksied (E171). OxyContin 20 mg Prolonged Release Tablet: Hipromellose (E464), Makrogol 400, Polisorbaat 80, Titaniumdioksied (E171), Ysteroksied (E172) OxyContin 40 mg Prolonged Release Tablet: Hipromellose (E464), Makrogol 400, Polisorbaat 80, Titaniumdioksied (E171), Ysteroksied (E172). OxyContin 80 mg Prolonged Release Tablet: Hipromellose (E464), Hiprolose, Makrogol 400, Titaniumdioksied (E171), Ysteroksied (E172), Indigo carmine (E132) kleurstof. 2. WAARVOOR WORD OxyContin Prolonged Release Tablets GEBRUIK: OxyContin Prolonged Release Tablets is n sterk analgetikum of pynstiller en behoort aan die opioïede groep. OxyContin Prolonged Release Tablets word gebruik vir die verligting van matige tot erge pyn by pasiënte met kanker en post-operatiewe pyn, nadat die gastroïntestinale funksie teruggekeer het. OxyContin Prolonged Release Tablets word gebruik vir die verligting van erge pyn wat die gebruik van n sterk opioïed analgetikum vereis. 16

17 3. VOORDAT OxyContin Prolonged Release Tablets GENEEM WORD: Moet nie OxyContin Prolonged Release Tablets neem as u allergies (hipersensitief) is teenoor die aktiewe bestanddeel oksikodoonhidrochloried of enige van die ander bestanddele; as u aan erge asemhalingsprobleme met n verlaagde toevoer van suurstof aan die bloed (hipoksie) en/of verhoogde koolstofdioksied versadiging van die bloed (hiperkapnie) ly; as u aan n langtermyn (chroniese) obstruktiewe longsiekte ly; as u n hartprobleem na langtermyn longsiekte (cor pulmonale) het; as u aan langtermyn (chroniese) brongiale asma ly; waar die klein derm nie behoorlik werk nie (paralitiese ileum); tydens swangerskap en borsvoeding; in die teenwoordigheid van erge long-, lewer- of niersiektes; indien u n tipe medisyne bekend as monoamienoksidaseïnhibeerders neem of as u hierdie tipe medisyne in die laaste twee weke gebruik het; in enige situasie waar opioïede teenaangedui is; indien u aan hoofbesering wat erge hoofpyn veroorsaak of u laat siek voel, ly; indien u aan erge pyn in u buik ly; indien u maag stadiger as wat dit moet ledig (vertraagde gastriese lediging); indien u aan voortgesette konstipasie (harde, nie dikwelse stoelgange) ly; vir 6 ure voor n operasie of vir die eerste 24 uur na n operasie; indien u aan seldsame genetiese probleme van galaktose intoleransie, die Lapp laktase tekort of glukose-galaktose malabsorpsie ly. 17

18 Neem spesiale sorg met OxyContin Prolonged Release Tablets by bejaardes of verswakte pasiënte; indien u n onder-aktiewe tireoïed (hipotireose) het, aangesien u n laer dosis van OxyContin Prolonged Release Tablets mag benodig; indien u swak adrenale klierfunksie het (Addison s disease); indien u prostaat probleme het; indien u n geestelike afwyking as gevolg van n infeksie het (toksiese psigose); indien u ooit verslaaf was aan alkohol of geneesmiddels; indien u voorheen aan onttrekkingsimptome soos agitasie, angs, bewing of sweet, na die staking van alkohol of geneesmiddels gely het; indien u inflammasie van die pankreas (pankreatitis) of probleme met u galblaas het; indien u n erge hoofpyn het of siek voel aangesien dit mag aandui dat die drukking in u skedel verhoog is; indien u lae bloeddruk (hipotensie) of lae bloedvolume (hipovolemie) het; indien u inflammatoriese ingewandsiekte het. Indien hierdie inligting op u van toepassing is of voorheen op u van toepassing was, gesels asseblief met u geneesheer. Gebruik OxyContin Prolonged Release Tablets met spesiale sorg in gevalle waar u aan alkohol of geneesmiddels verslaaf is of ooit was. OxyContin 80 mg Prolonged Release Tablets OxyContin 80 mg Prolonged Release Tablets moet nie deur pasiënte geneem word, wat nog nooit opioïede vantevore geneem het nie, aangesien hul potensie tot lewensbedreigende respiratoriese depressie in hierdie groep van pasiënte kan lei. 18

19 Kinders en Adolessente jonger as 18 jaar OxyContin Prolonged Release Tablets OxyContin Prolonged Release Tablets is nie by kinders en adolessente jonger as 18 jaar getoets nie. Daarom is veiligheid en effektiwiteit nie vasgestel nie en OxyContin Prolonged Release Tablets word nie by kinders en adolessente jonger as 18 jaar aanbeveel nie. Bejaarde persone By bejaarde pasiëte sonder lewer- en/of niersiekte, is n dosisaanpassing gewoonlik nie nodig nie. Neem van ander medisyne Lig asseblief u geneesheer of apteker in, indien u nou of onlangs enige ander medisyne, insluitend medisyne sonder 'n voorskrif, geneem het. Indien u OxyContin Prolonged Release Tablets saam met ander medisyne gebruik kan die effek van OxyContin Prolonged Release Tablets of die ander medisyne verander. OxyContin Prolonged Release Tablets moet nie gelyktydig saam met n tipe medisyne bekend as monoamienoksidaseïnhibeerder (voorbeelde sluit in tranielsipromien, fenelsien, isokarboksied, moklobemied en linesolied) geneem word nie, of as u hierdie tipe medisyne in die laaste twee weke geneem het. Lig u geneesheer of apteker in: indien u medisyne neem om u te help slaap (byvoorbeeld kalmeermiddels, hipnotika of sedeermiddels); indien u onlangs anestetika gekry het; indien u medisyne neem om depressie te behandel; indien u medisyne neem om psigiatriese- of geestesafwykings te behandel; indien u ander sterk analgetika of pynstillers neem; 19

20 indien u spierverslappers neem; indien u medisyne neem om hoë bloeddruk te behandel; indien u kinidien neem ( n medisyne om vinnige hartsnelheid te behandel); indien u simetidien neem ( n medisyne vir maagsere, slegte spysvertering of sooibrand); indien u antifungus medisyne neem (soos ketokonasool); indien u antibiotika neem (soos eritromisien). Neem van OxyContin Prolonged Release Tablets saam met voedsel en drank. U kan OxyContin Prolonged Release Tablets met of sonder voedsel neem. Drink van alkohol tydens u behandeling met OxyContin Prolonged Release Tablets kan u slaperig maak. Indien u geaffekteer word moet u dit vermy om alkohol te drink. Swangerskap en borsvoeding Moet nie OxyContin Prolonged Release Tablets tydens swangerskap gebruik nie. Die aktiewe bestanddeel oksikodoon word oor die plasenta vervoer na die organisme van die kind. Die langtermyn gebruik van OxyContin Prolonged Release Tablets tydens swangerskap kan tot onttrekkingsimptome by pasgebore babas lei. Indien tydens geboorte geneem word, kan asemhalingsprobleme by die kind voorkom. Moet nie OxyContin Prolonged Release Tablets tydens periodes van borsvoeding neem nie, aangesien die aktiewe bestanddeel oksikodoon in borsmelk kan versprei. Vra u geneesheer of apteker vir advies voordat enige medisyne geneem of gebruik word. Bestuur en gebruik van masjienerie U kan slaperig voel wanneer u OxyContin Prolonged Release Tablets begin gebruik, of wanneer u na n hoër dosis oorskakel. Indien u geaffekteer word moet u nie bestuur of masjienerie gebruik nie. 20

21 Belangrike inligting aangaande sommige van die bestanddele van OxyContin Prolonged Release Tablets OxyContin Prolonged Release Tablets bevat laktose. Indien u geneesheer u ingelig het dat u n intoleransie teenoor sommige suikers het, kontak u geneesheer voordat u OxyContin Prolonged Release Tablets neem. 4. HOE OM OxyContin Prolonged Release Tablets TE NEEM Neem altyd OxyContin Prolonged Release Tablets presies soos deur u geneesheer voorgeskryf. Moet nie u dosis soos deur u geneesheer aanbeveel, oorskry nie. U moet met u geneesheer of apteker nagaan as u nie seker is nie. Tensy anders voorgeskryf deur u geneesheer, is die gebruiklike dosis vir volwassenes ouer as 18 jaar een OxyContin 10 mg Prolonged Release Tablets (10 mg oksikodoonhidrochloried) met 12 uur intervalle. Sommige pasiënte kan voordeel trek uit n dosis van 5 mg om sodoende die newe-effekte te verminder. U geneesheer sal egter die dosis nodig om u pyn te behandel, voorskryf. Indien u voel dat u steeds in pyn is, of die effek te sterk is terwyl u OxyContin Prolonged Release Tablets neem, bespreek dit met u geneesheer. Sluk die verlengde vrystellingstablette heel in, om die vrystelling van die aktiewe bestanddeel nie oor n verlengde periode van tyd (verlengde vrystelling) te verswak nie. Sommige pasiënte wat OxyContin Prolonged Release Tablets op n vasgestelde tydskedule ontvang, vereis onmiddelike vrystelling pynstillers vir vinnige verligting van deurbraak pyn. OxyContin Prolonged Release Tablets is nie aangedui vir die behandeling van deurbraak pyn nie. 21

22 Bejaarde persone By bejaarde pasiënte sonder nier- en/of lewersiekte, is dosisaanpassings gewoonlik nie nodig nie. Hoë risiko pasiënte Pasiënte met nier- en/of lewersiekte wie nie voorheen opioïede ontvang het nie, moet aanvanklik helfte van die aanbevole volwasse dosis neem. Dit is ook van toepassing tot pasiënte met lae liggaamsmassa en pasiënte wat medisyne teen n stadiger snelheid metaboliseer. Metode van toediening en gebruiksduur Sluk die verlengde vrystellingstablette heel in sonder om hul te kou en met genoegsame vloeistof (halwe glas water) in die oggend en aand in ooreenstemming met n vasgestelde tydskedule (bv. in die oggend om 8 vm., en in die aand om 8 nm.). U kan OxyContin Prolonged Release Tablets met of sonder voedsel neem. Ten einde verswakking van die verlengde vrystellingseffek van die tablette te vermy moet die verlengde vrystellingstablette heel ingesluk word en nie toegelaat word om gebreek, gekou of fyngedruk te word nie. Die inname van gebreekte, gekoude of fyngedrukte tablette lei tot spoediger vrystelling van die aktiewe bestanddeel en die absorpsie van n potensieel fatale dosis van die aktiewe bestanddeel oksikodoon (sien onder Indien u meer OxyContin Prolonged Release Tablets geneem het as wat u moes ). OxyContin Prolonged Release Tablets is alleenlik vir mondelingse gebruik (mondelingse inname van heel tablette). Onbehoorlike inspuiting (inspuiting in n bloedvaat) van die opgeloste tablette moet nie gedoen word nie, aangesien dit tot ernstige newe-effekte wat fatal kan wees, lei. 22

23 U kan die residu van die tablet in u stoelgang sien. Moet nie bekommer nie, aangesien die aktiewe bestanddeel oksikodoon vroeër vrygestel is terwyl die tablet deur die gastriese sisteem beweeg het en begin het om effektief te wees in u liggaam. Indien u meer OxyContin Prolonged Release Tablets geneem het as wat u moet, of as iemand per ongeluk u tablette ingesluk het Laat weet u geneesheer of hospitaal dadelik. Persone wat n oordosis geneem het kan baie slaperig en siek voel. Hulle kan ook moeilike asemhaling hê wat tot bewusteloosheid of selfs dood kan lei, en kan noodbehandeling in n hospital benodig. Wanneer mediese hulp gesoek word, maak seker dat u hierdie pamflet en enige oorblywende tablette saam met u neem om u geneesheer te wys. Indien u vergeet om OxyContin Prolonged Release Tablets te neem Indien u n kleiner dosis van OxyContin Prolonged Release Tablets as wat voorgeskryf is neem, of as u geheel en al vergeet het om u dosis te neem, kan dit tot onbevredigende en/of onvoldoende pynverligting lei. Indien u een keer vergeet het om u dosis te neem, kan u dit later neem slegs as die volgende gewone dosis vir meer as 8 uur later geskeduleer is. U kan dan voortgaan om u gewone skedule te volg. Indien die tyd na die volgende dosis korter is, neem die verlengde vrystellingstablet maar stel die volgende dosis uit met 8 uur. In prinsiep moet u nooit OxyContin Prolonged Release Tablets meer dikwels as die 8- uurlikse intervalle neem nie. Moet nooit n dubbele hoeveelheid van die enkeldosis neem nie. Indien u OxyContin Prolonged Release Tablets staak 23

24 Moet nie OxyContin Prolonged Release Tablets staak sonder dat u u geneesheer in kennis gestel het nie. Indien u die gebruik van u tablette wil staak, bespreek dit eers met u geneesheer. Hulle sal u inlig hoe om dit te doen, gewoonlik deur die dosis geleidelik te verminder sodat u nie onaangename effekte ondervind nie. Indien u enige verdere vrae oor die gebruik van hierdie produk het, vra u geneesheer of apteker. 5. MOONTLIKE NEWE-EFFEKTE Soos met alle medisyne kan OxyContin Prolonged Release Tablets newe-effekte veroorsaak, hoewel nie almal dit ondervind nie. Alle medisyne kan allergiese reaksies veroorsaak, alhoewel ernstige allergiese reaksies seldsaam is. Lig u geneesheer onmiddellik in as u skielike gehyg, moeilike asemhaling, swelling van die ooglede, gesig of lippe, uitslag of gejeuk veral die wat die hele liggaam bedek, kry. Die mees ernstige newe-effek is n toestand waar u stadiger of swakker asemhaal as wat verwag word (respiratoriese depressie). Soos met alle sterk pynstillers, is daar n risiko dat u verslaaf of afhanklik kan raak aan OxyContin Prolonged Release Tablets. Algemene newe-effekte (Affekteer waarskynlik meer as 1 uit 100 persone wat OxyContin Prolonged Release Tablets neem.) Meeste mense sal konstipasie kry wanneer hul OxyContin Prolonged Release Tablets neem. U geneesheer kan n purgeermiddel voorskryf om die probleem te oorkom. 24

25 U kan siek voel of braak (siek wees) wanneer u hierdie verlengde vrystellingstablette neem, maar dit behoort normaalweg na n paar dae te verdwyn, maar u geneesheer kan n anti-braking medisyne voorskryf indien die probleem voortduur. U mag vind dat u meer slaperig voel as normaalweg wanneer u begin om u tablette te neem of as die dosis verhoog word. Dit sal verdwyn na n paar dae. Die volgende newe-effekte is ook algemeen aangemeld by pasiënte wat met OxyContin Prolonged Release Tablets behandel word: Droë mond, verlies aan aptyt, slegte spysvertering, buikpyn of -ongemak, diarree; Hoofpyn, verwarring, gevoel van ongewone swakheid, duiseligheid, angs, senuweeagtigheid, sametrekkings, moeilik om te slaap, abnormale denke of drome; Moeilike asemhaling, gehyg, kortasemheid, verlaagde hoesrefleks; Uitslag, jeukerige vel; Sweet, koue rillings. Nie algemene newe-effekte (Affekteer waarskynlik minder as 1 uit 100 persone wat OxyContin Prolonged Release Tablets neem) Moeilike sluk, winde opbreek, hik, gastroïntestinale afwykings (bv. maagongesteldheid), verandering in smaak; n Gevoel van duiseligheid of alles wat draai gevoel, gevoel van floute veral as u opstaan, hallusinasie, gemoedsveranderinge, depressie, n gevoel van buitengewone blydskap, rusteloosheid, agitasie, algemene gevoel van ongesteldheid, verlies aan geheue, bewing, moeilike spraak, verlaagde sensitiwiteit teenoor pyn of aanraking, prikkelgevoel of gevoelloosheid, stuipe, stuiptrekkings of konvulsies, dowwe visie; Moeilike urien pasering, impotensie, verlaagde seksuele dryf, afwesigheid van 25

26 maandstondes; Vinnige hartklop, lae bloeddruk, blosing van die vel; Dehidrasie, dors, swelling van die hande, enkels, of voete; Droë vel, erge afskilfering of vervel van die vel; Rooiheid van die gesig, afname in die grootte van die pupille in die oog, spierspasma, hoë temperatuur; n Nodigheid om toenemend n hoër dosis van OxyContin Prolonged Release Tablets te neem om dieselfde vlak van pynverligting (toleransie) te verwerf; Onttrekkingsimptome soos agitasie, angs, palpitasies, bewing of sweet met die staking van OxyContin Prolonged Release Tablets. OxyContin Prolonged Release Tablets kan die resultate van bloedtoetse om te toets of die lewer ordentlik werk affekteer, maar dit is nie algemeen nie. Nie al die newe-effekte vir OxyContin Prolonged Release Tablets aangemeld, is in die pamflet ingesluit nie. Indien enige van die newe-effekte ernstig word, of as u enige newe-effekte wat nie in hierdie pamflet gelys is nie waarneem, raadpleeg u geneesheer, apteker of ander gesondheidsorgspesialis vir advies. 6. HOE OM OxyContin Prolonged Release Tablets TE BEWAAR: Bewaar hierdie medisyne buite die bereik en sig van kinders. Bewaar benede 25 o C. Bewaar in oorspronkilke verpakking in die kartonhouer om sodoende teen lig te beskerm. Moet nie OxyContin Prolonged Release Tablets na die vervaldatum wat op die stulpverpakking en karton na Expiry date geskryf is, gebruik nie. Die vervaldatum verwys na die laaste dag van die maand. 7. AANBIEDING VAN OxyContin Prolonged Release Tablets 26

27 OxyContin 5 mg Prolonged Release Tablets word verskaf in deursigtige PVC en aluminium foelie stulpverpakkings van 28. OxyContin 10 mg Prolonged Release Tablets word verskaf in deursigtige PVC en aluminium foelie stulpverpakkings van 28. OxyContin 20 mg Prolonged Release Tablets word verskaf in deursigtige PVC en aluminium foelie stulpverpakkings van 28. OxyContin 40 mg Prolonged Release Tablets word verskaf in deursigtige PVC en aluminium foelie stulpverpakkings van 28. OxyContin 80 mg Prolonged Release Tablets word verskaf in deursigtige PVC en aluminium foelie stulpverpakkings van IDENTIFIKASIE VAN OxyContin Prolonged Release Tablets: OxyContin 5 mg Prolonged Release Tablets is vaalblou, ronde, bikonvekse, filmbedekte tablette met OC op een kant en 5 op die ander kant gedruk. OxyContin 10 mg Prolonged Release Tablets is wit, ronde, bikonvekse, filmbedekte tablette met OC op een kant en 10 op die ander kant gedruk. OxyContin 20 mg Prolonged Release Tablets is pienk, ronde, bikonvekse, filmbedekte tablette met OC op een kant en 20 op die ander kant gedruk. OxyContin 40 mg Prolonged Release Tablets is geel, ronde, bikonvekse, filmbedekte tablette met OC op een kant en 40 op die ander kant gedruk. OxyContin 80 mg Prolonged Release Tablets is groen, ronde, bikonvekse, filmbedekte tablette met OC op een kant en 80 op die ander kant gedruk. 9. REGISTRASIENOMMERS: OxyContin 5 mg Prolonged Release Tablets: 41/2.9/1098 OxyContin 10 mg Prolonged Release Tablets: 41/2.9/1099 OxyContin 20 mg Prolonged Release Tablets: 41/2.9/

28 OxyContin 40 mg Prolonged Release Tablets: 41/2.9/1101 OxyContin 80 mg Prolonged Release Tablets: 41/2.9/ NAAM EN BESIGHEIDSADRES VAN DIE HOUER VAN DIE REGISTRASIESERTIFIKAAT: Mundipharma (Edms) Bpk Posbus Claremont 7735 Suid-Afrika 11. DATUM VAN PUBLIKASIE VAN DIE VOUBILJET: 9 Oktober 2009 = OxyContin is 'n geregistreerde handelsmerk 28

Package leaflet: Information for the user. Sevredol 10 mg, 20 mg and 50 mg tablets Morphine sulfate

Package leaflet: Information for the user. Sevredol 10 mg, 20 mg and 50 mg tablets Morphine sulfate Package leaflet: Information for the user Sevredol 10 mg, 20 mg and 50 mg tablets Morphine sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

If you are going to have an operation, please tell the doctor at the hospital that you are taking these tablets.

If you are going to have an operation, please tell the doctor at the hospital that you are taking these tablets. Package leaflet: Information for the user MST Continus 5 mg, 10 mg, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg prolonged release tablets Morphine sulfate Read all of this leaflet carefully before you start

More information

If you are going to have an operation, please tell the doctor at the hospital that you are taking these tablets.

If you are going to have an operation, please tell the doctor at the hospital that you are taking these tablets. Package leaflet: Information for the user MST Continus 5 mg, 10 mg, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg prolonged release tablets Morphine sulfate Read all of this leaflet carefully before you start

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Longtec 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg and 120 mg prolonged release tablets Oxycodone hydrochloride Read all of this leaflet carefully before

More information

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol) Package leaflet: Information for the user Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol) Read all of this leaflet carefully before you start taking this medicine because

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.

More information

This leaflet answers some common questions about Momex SR Tablets.

This leaflet answers some common questions about Momex SR Tablets. Momex SR Modified (Sustained) Release Tablets [Morphine sulphate] CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Momex SR Tablets. It does not contain

More information

If you are going to have an operation, please tell the doctor at the hospital that you are taking this suspension.

If you are going to have an operation, please tell the doctor at the hospital that you are taking this suspension. Package leaflet: Information for the user MST Continus 20 mg, 30 mg, 60 mg, 100 mg and 200 mg prolonged-release suspensions Morphine sulfate Read all of this leaflet carefully before you start taking this

More information

2. What you need to know before you use OxyNorm injection

2. What you need to know before you use OxyNorm injection Package leaflet: Information for the user OxyNorm 50 mg/ml, solution for injection or infusion Oxycodone hydrochloride Read all of this leaflet carefully before you start using this medicine because it

More information

OXYCODONE CONTROLLED RELEASE TABLETS

OXYCODONE CONTROLLED RELEASE TABLETS 1 Consumer Medicine Information OXYCODONE CONTROLLED RELEASE TABLETS Oxycodone hydrochloride Controlled release tablets (Matrix Formulation) 5mg, 10 mg, 20 mg, 40 mg & 80 mg What is in this leaflet Please

More information

Package leaflet: Information for the user. Shortec 5 mg, 10 mg and 20 mg capsules, hard Oxycodone hydrochloride

Package leaflet: Information for the user. Shortec 5 mg, 10 mg and 20 mg capsules, hard Oxycodone hydrochloride Package leaflet: Information for the user Shortec 5 mg, 10 mg and 20 mg capsules, hard Oxycodone hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains

More information

PATIENT INFORMATION LEAFLET CARZIN XL

PATIENT INFORMATION LEAFLET CARZIN XL SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it

More information

Consumer Medicine Information

Consumer Medicine Information Consumer Medicine Information TRAMAL SR Tramadol hydrochloride Sustained Release Tablets What is in this leaflet? This leaflet answers some common questions about Tramal SR. It does not contain all the

More information

Q&A. YOUR QUESTIONS ANSWERED. A PATIENT S GUIDE TO Shortec (OXYCODONE HYDROCHLORIDE) CAPSULES

Q&A. YOUR QUESTIONS ANSWERED. A PATIENT S GUIDE TO Shortec (OXYCODONE HYDROCHLORIDE) CAPSULES Q&A i YOUR QUESTIONS ANSWERED. A PATIENT S GUIDE TO Shortec (OXYCODONE HYDROCHLORIDE) CAPSULES Contents General information What is Shortec?...3 Why have I been prescribed Shortec?...3 Why has my medicine

More information

PATIENT INFORMATION LEAFLET TAPENCET ER 50 (TAPENTADOL EXTENDED RELEASE 50 MG, TABLETS)

PATIENT INFORMATION LEAFLET TAPENCET ER 50 (TAPENTADOL EXTENDED RELEASE 50 MG, TABLETS) PATIENT INFORMATION LEAFLET TAPENCET ER 50 (TAPENTADOL EXTENDED RELEASE 50 MG, TABLETS) Read this entire leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read

More information

XYZAL 5 MG FILM-COATED TABLET

XYZAL 5 MG FILM-COATED TABLET XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,

More information

1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR

1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR PACKAGE LEAFLET: INFORMATION FOR THE USER Oxcarbazepine 150/300/600 mg Film-Coated Tablets (Oxcarbazepine) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER SALAGEN 5 mg film-coated tablets Pilocarpine hydrochloride Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may

More information

TRAMAL SR Sustained Release Tablets

TRAMAL SR Sustained Release Tablets TRAMAL SR Sustained Release Tablets Tramadol hydrochloride Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about Tramal SR. It does not contain all the

More information

Package leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium)

Package leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) PACKAGE LEAFLET Package leaflet: Information for the user Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) Read all of this leaflet carefully before you start taking this medicine because

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Irbesartan 75mg Film-coated Tablets Irbesartan 150mg Film-coated Tablets Irbesartan 300mg Film-coated Tablets irbesartan Read all of this leaflet carefully before

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) PACKAGE LEAFLET: INFORMATION FOR THE USER DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need

More information

Hoe kan ek my maatjie wat kanker het help?

Hoe kan ek my maatjie wat kanker het help? Hoe kan ek my maatjie wat kanker het help? Wat is kanker? Kanker kan beskryf word as normale en gesonde selle in jou liggaam wat verander het in ongesonde kankerselle. Daar is baie redes vir hierdie veranderinge

More information

Package leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide

Package leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide Package leaflet: Information for the user Flutamid Stada 250 mg tablets Flutamide Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed

More information

ATORIS 10, 20, 40 mg film-coated tablets

ATORIS 10, 20, 40 mg film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,

More information

PATIENT INFORMATION LEAFLET TEXAMER

PATIENT INFORMATION LEAFLET TEXAMER SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam)

PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam) PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read

More information

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR

Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) 1. WHAT LODINE SR TABLETS ARE AND WHAT THEY ARE USED FOR Patient Information Leaflet Lodine* SR Tablets 600mg (etodolac) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any

More information

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets

RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RANIBOS 150mg Film-coated tablets; 300mg Film-coated tablets RANITIDINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information

More information

Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets

Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets Pizotifen (as malate) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it

More information

Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate)

Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Package leaflet: Information for the user. Uniphyllin Continus 200 mg, 300 mg and 400 mg prolonged-release tablets Theophylline

Package leaflet: Information for the user. Uniphyllin Continus 200 mg, 300 mg and 400 mg prolonged-release tablets Theophylline Package leaflet: Information for the user Uniphyllin Continus 200 mg, 300 mg and 400 mg prolonged-release tablets Theophylline Read all of this leaflet carefully because it contains important information

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Naltrexone 50 mg film-coated tablets (Naltrexone hydrochloride)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Naltrexone 50 mg film-coated tablets (Naltrexone hydrochloride) PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Naltrexone 50 mg film-coated tablets (Naltrexone hydrochloride) Read all of this leaflet carefully before you start taking this medicine. - Keep

More information

TREANA 5mg and 10mg Film-coated Tablets

TREANA 5mg and 10mg Film-coated Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER TREANA 5mg and 10mg Film-coated Tablets OLANZAPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,

More information

Package leaflet: Information for the user PALEXIA SR 50 mg, 100 mg, 150 mg, 200 mg and 250 mg prolonged-release tablets.

Package leaflet: Information for the user PALEXIA SR 50 mg, 100 mg, 150 mg, 200 mg and 250 mg prolonged-release tablets. Package leaflet: Information for the user PALEXIA SR 50 mg, 100 mg, 150 mg, 200 mg and 250 mg prolonged-release tablets Tapentadol Read all of this leaflet carefully before you start taking this medicine

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Cinacalcet Devatis 30 mg filmomhulde tabletten Cinacalcet Devatis 60 mg filmomhulde tabletten Cinacalcet Devatis 90 mg filmomhulde tabletten Cinacalcet Read

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin PACKAGE LEAFLET: INFORMATION FOR THE USER XIFAXANTA 200 mg film-coated tablets Rifaximin Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

SIOFOR mg film-coated tablets

SIOFOR mg film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER SIOFOR 1000 1000mg film-coated tablets For use in children from 10 years and adults METFORMIN HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics

More information

Consumer Medicine Information

Consumer Medicine Information Consumer Medicine Information Trade Name: ZOLPIDEM-DP Active Ingredient: Zolpidem tartrate Warning: Zolpidem may be associated with unusual and potentially dangerous behaviours whilst apparently asleep.

More information

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET

PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET PROPOSED PATIENT INFORMATION LEAFLET FOR PHARMA DYNAMICS CLOPIDOGREL 75 mg PATIENT INFORMATION LEAFLET SCHEDULING STATUS S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM PHARMA DYNAMICS CLOPIDOGREL

More information

PACKAGE LEAFLET: INFORMATION FOR USER ROPINIROLE 2 mg FILM-COATED TABLETS. Ropinirole

PACKAGE LEAFLET: INFORMATION FOR USER ROPINIROLE 2 mg FILM-COATED TABLETS. Ropinirole PACKAGE LEAFLET: INFORMATION FOR USER ROPINIROLE 0.25 mg FILM-COATED TABLETS ROPINIROLE 0.5 mg FILM-COATED TABLETS ROPINIROLE 1 mg FILM-COATED TABLETS ROPINIROLE 2 mg FILM-COATED TABLETS Ropinirole Read

More information

Package leaflet: Information for the user. OxyNorm 5 mg, 10 mg and 20 mg capsules, hard Oxycodone hydrochloride

Package leaflet: Information for the user. OxyNorm 5 mg, 10 mg and 20 mg capsules, hard Oxycodone hydrochloride Package leaflet: Information for the user OxyNorm 5 mg, 10 mg and 20 mg capsules, hard Oxycodone hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains

More information

APOHEALTH Diarrhoea Relief PLUS

APOHEALTH Diarrhoea Relief PLUS APOHEALTH Diarrhoea Relief PLUS Chewable Tablets Contains the active ingredient Loperamide hydrochloride and Simethicone Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195

More information

OXYCODONE CONTROLLED RELEASE TABLETS

OXYCODONE CONTROLLED RELEASE TABLETS 1 Consumer Medicine Information OXYCODONE CONTROLLED RELEASE TABLETS Oxycodone hydrochloride Controlled release tablets 10 mg, 20 mg, 40 mg and 80 mg What is in this leaflet Please read this leaflet carefully

More information

Dulcolax 5 mg, film-coated tablets

Dulcolax 5 mg, film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Dulcolax 5 mg, film-coated tablets BISACODYL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which

More information

SANDOMIGRAN. 0.5mg tablet Pizotifen malate

SANDOMIGRAN. 0.5mg tablet Pizotifen malate SANDOMIGRAN 0.5mg tablet Pizotifen malate What is in this leaflet This leaflet answers some common questions about Sandomigran. It does not contain all the available information. It does not take the place

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Bluefish 1000 mg film-coated tablets Valaciclovir

PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Bluefish 1000 mg film-coated tablets Valaciclovir PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Bluefish 1000 mg film-coated tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You

More information

CONSUMER MEDICINE INFORMATION

CONSUMER MEDICINE INFORMATION CONSUMER MEDICINE INFORMATION Arrow - Tramadol Tramadol 50 mg capsules What is in this leaflet This leaflet answers some common questions about ARROW - TRAMADOL. It does not contain all of the available

More information

Package leaflet: Information for the user Tylex 30 mg / 500 mg Effervescent Tablets. Codeine phosphate hemihydrate, Paracetamol

Package leaflet: Information for the user Tylex 30 mg / 500 mg Effervescent Tablets. Codeine phosphate hemihydrate, Paracetamol Package leaflet: Information for the user Tylex 30 mg / 500 mg Effervescent Tablets Codeine phosphate hemihydrate, Paracetamol Read all of this leaflet carefully before you start taking this medicine because

More information

PATIENT INFORMATION LEAFLET DYNARB RANGE

PATIENT INFORMATION LEAFLET DYNARB RANGE SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNARB 75 mg tablets DYNARB 150 mg tablets DYNARB 300 mg tablets Read all of this leaflet carefully before you start taking DYNARB.

More information

Package leaflet: Information for the user. ARICEPT 10 mg Film Coated Tablets (Donepezil Hydrochloride)

Package leaflet: Information for the user. ARICEPT 10 mg Film Coated Tablets (Donepezil Hydrochloride) Package leaflet: Information for the user ARICEPT 5 mg Film Coated Tablets ARICEPT 10 mg Film Coated Tablets (Donepezil Hydrochloride) Read all of this leaflet carefully before you start taking this medicine

More information

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC. SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNAFLOC 250 (tablets) DYNAFLOC 500 (tablets) DYNAFLOC 750 (tablets) Read this entire leaflet carefully before you start taking

More information

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide Package leaflet: Information for the user Burinex 5 mg Tablets bumetanide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep

More information

Otezla (apremilast) film coated tablets

Otezla (apremilast) film coated tablets New Zealand Consumer Medicine Information Otezla (apremilast) film coated tablets WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Otezla. It does not contain all the available

More information

Package Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets

Package Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets PACKAGE LEAFLET Package Leaflet: Information for the user Methocarbamol 750mg Film-Coated Tablets Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Patient Information leaflet

Patient Information leaflet Patient Information leaflet CARDISEC (90 MG, 120 MG AND 180 MG) DILTIAZEM HYDROCHLORIDE PROLONGED- RELEASE CAPSULES USP) Read all of this leaflet carefully before you start taking this medicine because

More information

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine. TRIPROLIDINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains triprolidine. This leaflet is intended to provide information on the active ingredient

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. PROSCAR 5 mg Film-coated Tablets (finasteride)

PACKAGE LEAFLET: INFORMATION FOR THE USER. PROSCAR 5 mg Film-coated Tablets (finasteride) PACKAGE LEAFLET: INFORMATION FOR THE USER PROSCAR 5 mg Film-coated Tablets (finasteride) This medicine is for use in men only Read all of this leaflet carefully before you start to take this medicine.

More information

JURNISTA Hydromorphone hydrochloride

JURNISTA Hydromorphone hydrochloride Hydromorphone hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about prolonged-release tablets. It does not contain all the available information.

More information

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium)

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium) Package leaflet: Information for the user Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium) Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Alfuzosin HCl Ranbaxy 10 mg tablets, prolonged-release tablets Alfuzosin hydrochloride Read all of this leaflet carefully before using this medicine. - Keep this

More information

PACKAGE LEAFLET DIASTABOL 50 MG TABLETS. Version 1.0 1

PACKAGE LEAFLET DIASTABOL 50 MG TABLETS. Version 1.0 1 PACKAGE LEAFLET DIASTABOL 50 MG TABLETS 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Diastabol 50 mg tablets miglitol Read all of this leaflet carefully before you start taking this medicine. - Keep this

More information

NORVASC 5 mg and 10 mg tablets

NORVASC 5 mg and 10 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER NORVASC 5 mg and 10 mg tablets AMLODIPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which

More information

PACKAGE LEAFLET. Page 1 of 6

PACKAGE LEAFLET. Page 1 of 6 PACKAGE LEAFLET Page 1 of 6 Package leaflet: Information for the patient Procyclidine Hydrochloride 5 mg Tablets (procyclidine hydrochloride) Read all of this leaflet carefully before you start taking

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency

More information

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin Package leaflet: Information for the patient Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin Read all of this leaflet carefully before you start taking this medicine because

More information

Pravat 40 mg tablets. Pravastatin sodium

Pravat 40 mg tablets. Pravastatin sodium Package leaflet: Information for the patient Pravat 10 mg tablets Pravat 20 mg tablets Pravat 40 mg tablets Pravastatin sodium Read all of this leaflet carefully before you start taking this medicine because

More information

Onglyza CONSUMER MEDICINE INFORMATION

Onglyza CONSUMER MEDICINE INFORMATION What is in this leaflet Onglyza Saxagliptin 2.5 mg and 5 mg film coated tablets CONSUMER MEDICINE INFORMATION This leaflet answers some of the common questions people ask about Onglyza. It does not contain

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. NEFOXEF 120 MG FILM-COATED TABLETS NEFOXEF 180 MG FILM-COATED TABLETS Fexofenadine hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. NEFOXEF 120 MG FILM-COATED TABLETS NEFOXEF 180 MG FILM-COATED TABLETS Fexofenadine hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER NEFOXEF 120 MG FILM-COATED TABLETS NEFOXEF 180 MG FILM-COATED TABLETS Fexofenadine hydrochloride Read all of this leaflet carefully before you start using this

More information

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before

More information

2 What you need to know before you take Zantac

2 What you need to know before you take Zantac Package leaflet: Information for the user Zantac Tablets 150 mg and 300 mg ranitidine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

Package leaflet: Information for the patient. Felodipin AstraZeneca 10 mg prolonged-release tablets. felodipine

Package leaflet: Information for the patient. Felodipin AstraZeneca 10 mg prolonged-release tablets. felodipine Package leaflet: Information for the patient Felodipin AstraZeneca 2.5 mg prolonged-release tablets Felodipin AstraZeneca 5 mg prolonged-release tablets Felodipin AstraZeneca 10 mg prolonged-release tablets

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Oxycodone/Naloxone Glenmark 5 mg/2.5 mg prolonged-release tablets Oxycodone/Naloxone Glenmark 10 mg/5 mg prolonged-release tablets Oxycodone/Naloxone Glenmark

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Sandoz B.V. Page 1/8 Package leaflet: Information for the user Pioglitazon Lek 15 mg, tabletten Pioglitazon Lek 30 mg, tabletten Pioglitazon Lek 45 mg, tabletten Pioglitazone Read all of this leaflet carefully

More information

1. What Solpadol is and what it is used for

1. What Solpadol is and what it is used for PATIENT INFORMATION LEAFLET SOLPADOL 30mg/500mg CAPLETS Codeine Phosphate and Paracetamol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read

More information

Share the important information in this Medication Guide with members of your household.

Share the important information in this Medication Guide with members of your household. Medication Guide BUPRENORPHINE (BUE-pre-NOR-feen) and NALOXONE (nal-ox-one) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine and naloxone sublingual tablets in a secure place away from children.

More information

MORPHINE MR APOTEX Modified Release tablets Contains the active ingredient morphine sulfate pentahydrate

MORPHINE MR APOTEX Modified Release tablets Contains the active ingredient morphine sulfate pentahydrate MORPHINE MR APOTEX Modified Release tablets Contains the active ingredient morphine sulfate pentahydrate Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this

More information

KAMIREN PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT KAMIREN IS AND WHAT IT IS USED FOR

KAMIREN PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT KAMIREN IS AND WHAT IT IS USED FOR PACKAGE LEAFLET: INFORMATION FOR THE USER KAMIREN 2 mg, 4 mg TABLETS DOXAZOSIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII)

MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away from children. If a child accidentally takes ZUBSOLV, this is a

More information

Package leaflet: Information for the user. Ormetone 40 mg/20 mg prolonged-release tablets. oxycodone hydrochloride / naloxone hydrochloride

Package leaflet: Information for the user. Ormetone 40 mg/20 mg prolonged-release tablets. oxycodone hydrochloride / naloxone hydrochloride Package leaflet: Information for the user Ormetone 5 mg/2.5 mg prolonged-release tablets Ormetone 10 mg/5 mg prolonged-release tablets Ormetone 20 mg/10 mg prolonged-release tablets Ormetone 40 mg/20 mg

More information

TEMGESIC Injection Buprenorphine (as hydrochloride)

TEMGESIC Injection Buprenorphine (as hydrochloride) TEMGESIC Injection Buprenorphine (as hydrochloride) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about TEMGESIC. It does not contain all the available

More information

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You

More information

What is in this leaflet

What is in this leaflet Package leaflet: Information for the user 2.5 mg film-coated tablets Naratriptan Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

Maxilief Effervescent Tablets

Maxilief Effervescent Tablets Package Leaflet: Information for the user Maxilief Effervescent Tablets Paracetamol Codeine Phosphate Hemihydrate Caffeine 500mg 8mg 30mg Read all of this leaflet carefully before you start taking this

More information

Consumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.

Consumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules. Clindamycin hydrochloride Capsules 150 mg What is in this leaflet Consumer Medicine Information TOPICIL Please read this leaflet carefully before you start using Topicil Capsules. This leaflet answers

More information

PACKAGE LEAFLET. Page 1 of 8

PACKAGE LEAFLET. Page 1 of 8 PACKAGE LEAFLET Page 1 of 8 Package leaflet: Information for the patient Temazepam 10mg and 20mg tablets (Temazepam) Read all of this leaflet carefully before you start taking this medicine because it

More information

Package leaflet: Information for the patient. Risedronate sodium 35 mg film-coated tablets. Risedronate sodium

Package leaflet: Information for the patient. Risedronate sodium 35 mg film-coated tablets. Risedronate sodium Package leaflet: Information for the patient Risedronate sodium 35 mg film-coated tablets Risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Luventa XL 8 mg prolonged-release capsules, hard Luventa XL 16 mg prolonged-release capsules, hard Luventa XL 24 mg prolonged-release capsules, hard

Luventa XL 8 mg prolonged-release capsules, hard Luventa XL 16 mg prolonged-release capsules, hard Luventa XL 24 mg prolonged-release capsules, hard PACKAGE LEAFLET: INFORMATION FOR THE USER Luventa XL 8 mg prolonged-release capsules, hard Luventa XL 16 mg prolonged-release capsules, hard Luventa XL 24 mg prolonged-release capsules, hard Galantamine

More information

Dulcolax Tablets and Dulcolax Suppositories Bisacodyl

Dulcolax Tablets and Dulcolax Suppositories Bisacodyl Consumer Medicine Information Tablets and Suppositories Bisacodyl What is in this leaflet 1. What is used for 2. Before you use a) When you must not use b) Before you start to use c) Pregnancy d) Breastfeeding

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER ARICEPT Evess 5 mg Orodispersible Tablets ARICEPT Evess 10 mg Orodispersible Tablets (Donepezil Hydrochloride) You and your caregiver should read all of this leaflet

More information

FOR ANIMAL USE ONLY. BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0

FOR ANIMAL USE ONLY. BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0 FOR ANIMAL USE ONLY BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0 INDICATIONS Berenil R.T.U. cures and prevents Redwater in cattle and cures biliary fever in dogs and

More information

PATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE

PATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each

More information

*Gebaseer op die Nasionale Kanker Register Leeftyd risiko vir prostaatkanker 1:27. testikulêrekanker 1: peniskanker 1:1 114

*Gebaseer op die Nasionale Kanker Register Leeftyd risiko vir prostaatkanker 1:27. testikulêrekanker 1: peniskanker 1:1 114 *Gebaseer op die Nasionale Kanker Register 2010 Leeftyd risiko vir prostaatkanker 1:27 Leeftyd risiko vir testikulêrekanker Leeftyd risiko vir peniskanker 1:2 040 1:1 114 Prostaatkanker 1 uit 27 Suid-Afrikaanse

More information

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride Package leaflet: Information for the user Morfin Abcur 10 mg/ml, solution for injection morphine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains

More information